Press Releases

Press Releases

Date Title
09/14/20 Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
Recruitment for Phase 1 clinical study expected to start this month Data from ongoing hamster challenge study expected in October SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral vaccines that are administered by
09/08/20 Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies
Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission Vaxart’s oral tablet vaccine can overcome major challenges of injectable vaccines SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc.
09/03/20 Vaxart, Inc. to Participate in September Virtual Investor Conferences
- H.C. Wainwright : 22 nd Annual Global Investment Conference - September 14 th – 16 th - Sachs Associates : 20 th Annual Biotech in Europe Forum - September 21 st  – 24 th - SVB Leerink: CybeRx Series: Vaccine Forum - September 23 rd & – 24 th SOUTH SAN FRANCISCO, Calif. , Sept.
08/27/20 Vaxart Appoints Karen J. Wilson to its Board of Directors
SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced the appointment of Karen J.
08/10/20 Vaxart Announces IND Filed for COVID-19 Vaccine
SOUTH SAN FRANCISCO, Calif. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been
08/06/20 Vaxart Announces Second Quarter 2020 Results
Enhanced Leadership – New CEO in Q2 Ample Cash Runway following Financing by Notable Institutional Healthcare Investors SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by
07/16/20 Norovirus Gastroenteritis Costs an Estimated $10.6 Billion Each Year in the United States
Over 90% of norovirus' total annual cost is due to sporadic spread in the community. SOUTH SAN FRANCISCO, Calif. , July 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than
07/13/20 Vaxart Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility
RA Capital Management to own approximately 9.99% of the Company’s outstanding common stock SOUTH SAN FRANCISCO, Calif. , July 13, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by
06/26/20 Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed
OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates SOUTH SAN FRANCISCO, Calif. , June 26, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that its oral
06/25/20 Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year Through Large Scale Lyophilization, Tableting and Coating SOUTH SAN FRANCISCO, Calif. , June 25, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral